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Abstract: Thiomarinol and mupirocin are assembled on similar 
polyketide/fatty acid backbones and exhibit potent antibiotic activity 
against MRSA. They both contain a tetra-substituted tetrahydropyran 
(THP) ring essential for biological activity. Mupirocin is a mixture of 
pseudomonic acids (PAs). Isolation of the novel mupirocin P 
containing a 7-hydroxy-6-ketoTHP from a mupP strain and chemical 
complementation experiments confirm that the first step in the 
conversion of PA-B to the major product PA-A is oxidation at C-6. In 
addition, nine novel thiomarinol (TM) derivatives with different 
oxidation patterns decorating the central THP core have been isolated 
from gene deletion (tmlF). These metabolites are in accord with the 
THP ring formation and elaboration in thiomarinol following a similar 
order to that found in mupirocin biosynthesis, despite lacking some of 
the equivalent genes. Novel mupirocin-thiomarinol hybrids have been 
synthesised using mutasynthesis.  
Thiomarinols (1-6) are an unusual group of hybrid antibiotics 
produced by the marine bacterium Pseudoalteromonas sp. 
SANK73390 (Figure 1).[1] They combine close analogues of the 
clinically important agent, mupirocin (a mixture of pseudomonic 
acids, PA  A–C, 7-9)[2]  with the pyrrothine subunit of the holomycin 
class of antibiotics. Both thiomarinols and mupirocin display 
potent activity against MRSA (methicillin-resistant 
Staphylococcus aureus),[3] and belong to the trans-AT class of 
modular polyketide-derived antibiotics.[4] The mup biosynthetic 
gene cluster was one of the first of this class to be discovered,[5]  
but there are now more than 20 at least partially characterised, 
with many others known from genomic sequences.[4] 
Thiomarinols can be regarded as comprising three main elements: 
a highly functionalised polyketide-derived acid, which is esterified 
by 8-hydroxyoctanoic acid, which itself forms an amide with the 
bicyclic amino acid-derived pyrrothine. The major components 
TM-A 1 and PA-A 7 differ in the lack of a 10,11-epoxide, the 
presence of a 4-hydroxyl, a C8 rather than a C9 fatty acid, and the 
pyrrothine in TM-A.[6]  
The 6,7-dihydroxytetrahydropyran (THP) ring is necessary for the 
biological activity of mupirocin and thiomarinol, so elucidation of 
the biosynthetic mechanisms for ring formation and further 
modifications to the 6,7-diol is important. Mutational analysis of 
mupirocin biosynthesis showed somewhat counter-intuitively: (a) 
that the 8-hydroxyl of PA-B 8 has to be lost not gained, with 
feeding experiments confirming that PA-B is an intermediate in 
the biosynthesis of PA-A 7[7] and (b) that PA-C 9 is the product of 
a parallel pathway that branches from the main pathway (to PA-
A) following failure to undergo epoxidation of the 10,11-double 
bond.[8] Analyses of mutant strains[9] indicate that putative 
biosynthetic precursor 12 (Scheme 1) is cyclised and esterified to 
give PA-B with the tetrahydropyran ring. In addition, identification 
of minor metabolites with C5 and C7 fatty acid side-chains are in 
accord with elaboration of the 9-hydroxynonanoic acid moiety 
occurring by initial addition of 3-hydroxypropionate followed by 3 
successive MmpB-mediated chain elongations.[7b]  
 
 
 
 
Figure 1. Selected thiomarinols and pseudomonic acids. 
 
 
New insights into the mechanism of PA-B to PA-A 
conversion – MupP acts as a dehydratase.  
Conversion of PA-B 8 to PA-A 7 (replacing 8-OH with 8-H) has 
been shown to require MupU (CoA-ligase) and MacpE (ACP), 
MupO (P450), MupV (see below), MupC (enoate reductase) and 
MupF (ketoreductase) via the isolated intermediates mupirocin 
C1 14 and mupirocin F1 15, as shown in Scheme 1. Deletion of 
any of mupO, mupU, mupV or macpE all gave PA-B 8 as the 
major product along with the macrolactone 10.[8] The first step in 
the conversion of PA-B 8 to PA-A 7 is MupU catalysed ligation of 
PA-B to MacpE (Scheme 1) followed by oxidation (MupO). 
However, no metabolite corresponding to the putative -
hydroxyketone product 13 of MupO had been detected. Isolation 
and identification of these epoxide-containing metabolites is 
challenging as they are prone to rearrangements but are key to 
elucidating the remaining biosynthetic steps from PA-B to PA-A. 
Indeed PA-A itself is limited to mainly topical applications due to 
its instability in serum.[3]  
Our first goal was to establish the proposed 7-hydroxy-6-ketone 
13 as a biosynthetic intermediate to PA-A. Analysis of a mupP 
strain revealed an unstable metabolite with MW 514 and detailed 
1D and 2D NMR confirmed the structure of this key intermediate 
which is now named mupirocin P (13). 
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 Scheme 1.  MupP acts as a dehydratase in mupirocin biosynthesis 
We have shown previously that the OR domain of MmpE is 
responsible for epoxidation.[8] Thus a double mutant, 
mmpEOR/mupP strain was constructed. Gratifyingly, this 
produces the less labile desepoxy-mupirocin P 16 as the main 
metabolite along with a small amount of desepoxy-PA-B 17 
(Figure 2). MupP had not been previously assigned a function. 
Bioinformatic analysis indicates that it belongs to the 
glyoxalase/bleomycin resistance protein/dioxygenase 
superfamily but appears to act here overall as a dehydratase to 
give enol-ketone 14 (Scheme 1).  
 
 
 
Figure 2. HPLC trace of crude extract of the mmpEOR/mupP double mutant 
strain of P. fluorescens NCIMB 10586 
Previous mutasynthesis studies on mupirocin biosynthesis[8] 
showed that PA-B 8, mupirocin C1 14 and mupirocin F1 15 were 
all efficiently (15-50%) converted to PA-A 7 by mutant strains of 
P. fluorescens blocked in earlier parts of the pathway, thus 
confirming their role as intermediates in mupirocin biosynthesis.  
To investigate if the 7-hydroxy-6-ketone is also a true intermediate 
on the pathway, desepoxy-mupirocin P 16, isolated from the 
mmpEOR/mupP strain, was fed to cultures of the 
mmpEORmupW strain and LC-MS showed a peak with the 
same retention time as desepoxy-mupirocin P but with MW 484. 
The metabolite was isolated and NMR revealed that PA-C had 
been produced confirming that desepoxy-mupirocin P is indeed 
an intermediate in PA-C 9 biosynthesis (Scheme 2).  
Reanalysis of the MupV amino acid sequence, which had 
previously been identified as a putative oxidoreductase, revealed 
a second domain with ca. 30% sequence identity to many 
Pseudomonas hydrolases. These contain a GXCXG 
consensus sequence where cysteine replaces the more common 
nucleophilic serine and includes an amino transferase involved in 
shuffling intermediates between thiolation domains in the 
syringomycin biosynthetic pathway in Pseudomonas syringae.[10]  
Thus MupV may act as a thioesterase or perhaps in some related 
ACP transfer capacity. Previously deletion of mupV had provided 
few clues as this yielded PA-B 8 as the major product.[9c]  
However, in this study, feeding desepoxy-mupirocin P 16 to the 
mupV strain gave PA-C in accord with a Mup V activity being 
required before MupP leading to mupirocin P 13 (and desepoxy-
mupirocin P 16) (Schemes 1 and 2). 
 
 
 
Scheme 2.  Feeding 16 to either mmpEOR/mupW or mupV strains gives 
PA-C 9. 
 Thiomarinol biosynthesis 
The thiomarinol (tml) biosynthetic gene cluster was identified via 
complete genome sequencing of SANK73390, which was found 
to harbour a 97 kb plasmid consisting almost entirely of the 
thiomarinol biosynthetic genes.[11] These include multimodular 
trans-AT PKSs (tmpA, C and D), a putative FAS (tmpB) and 
associated tailoring and resistance genes (tmlA-Z) most of which 
exhibit high homology to counterparts in the mupirocin (mup) 
cluster (Figure S1). A non-ribosomal peptide synthetase (NRPS) 
linked to a set of tailoring enzymes (holA-H) similar to that recently 
shown to control holomycin biosynthesis in Streptomyces 
clavuligerus is also present.[12] We have produced mutant strains 
of SANK73390 in which the PKS and NRPS parts of the cluster 
have been insertionally deactivated. Analysis of WT, NRPS and 
tmlU mutant strains led to the isolation of marinolic acids A 18, A6 
20, and A4 21 lacking the pyrrothine (Figure 3).[13] Using a 
combination of genetic and isotopic labelling studies, we showed 
that the 8-hydroxyoctanoic acid side-chain is generated via 
successive chain extensions of a C4 precursor (4-hydroxybutyrate) 
derived from succinate, to give marinolic acids 18, 20 and 21 and 
that pyrrothine is assembled from two molecules of cysteine 
(HolA-D) prior to intact incorporation into thiomarinol.[13] It has 
recently been shown that TmlU acts as a substrate selective CoA 
ligase that activates marinolic acid as a thioester which in turn is 
the substrate for amide formation catalysed by the acyl 
transferase HolE.[14]  Analysis of the PKS mutant revealed a series 
of acyl-pyrrothines designated as xenorhabdins.[13] 
Marinolic acid A 18 has a similar structure to PA-A 7 but lacks the 
epoxide and has an additional 4-hydroxyl group. The tml pathway, 
however has only some of the homologues of the mup genes, viz. 
tmlW, T, O, P, C and F, but homologues of the stand alone ACP 
macpE, mupU and mupV are missing. The absence of these 
genes from the tml cluster raises the question of how the same 
overall conversion can be achieved with an apparently simpler 
gene set. We now report results which indicate that a similar set 
of intermediates are indeed involved in THP ring formation and 
further modification in both mupirocin and thiomarinol 
biosynthesis. 
 
 
 
Figure 3. Marinolic acids and acyl-pyrrothine metabolites isolated from WT and 
mutant strains of Pseudoalteromonas sp SANK73390 
Chemical investigation of ΔtmlF- late stage biosynthetic 
steps.  
Deletion of mupF (7-ketoreductase) in P. fluorescens releases a 
number of intermediates including mupirocin C1 14 and PA-B 8 
and related shunt products in addition to mupirocin F1 15 
(Scheme 1).[9b] TmlF, shows 33% amino acid sequence identity to 
MupF so it is likely to act as a 7-ketoreductase as does MupF in 
the final step in mupirocin biosynthesis, which converts mupirocin 
F1 15 to the dihydroxytetrahydropyran PA-A 7. Thus deletion of 
tmlF could release more intermediates and shunt products 
besides its own substrate analogous to the mupF deletion. 
 
 
 
Figure 4. Novel metabolites isolated from extracts of the ΔtmlF mutant of 
Pseudoalteromonas sp. SANK73390 
 
WT SANK73390 was cultivated on a modified marine broth 
medium (see SI for details) which significantly improved the 
production of the total thiomarinols. Using this medium, a yield of 
70–100 mg.L-1 TM-A 1 could be obtained, compared to 10-20 
mg.L-1 in previous studies.[6] Our aim was to carry out a set of 
gene KOs to parallel those carried out with mupirocin,[8,9]  but 
reverse genetics of SANK73390 proved to be problematic. We 
were however successful in making the key tmlF by the method 
previously reported[11] using approximately 500bp arms defining 
an in-frame deletion from aa 10 to aa 327 in TmlF.  
Analysis of extracts showed that as anticipated the production 
of thiomarinols A and C (1 and 2, Figure 1) was completely 
abolished, but the xenorhabdin acyl-pyrrothine metabolites were 
generated as normal. Further analysis of the HPLC trace 
indicated that various new thiomarinol-related metabolites were 
present albeit in minor amounts, 0.1 - 1.2 mg.L-1 (Figure 4). A 
major product among those minor metabolites was 8-hydroxy-
thiomarinol C 22. Its structure, and that of other metabolites 
reported herein, were determined by full NMR analysis and HR-
ESI-MS (see SI for details). The presence of an 8-hydroxy-THP 
ring as in PA-B 8 suggests that both biosynthetic pathways 
possess analogous pyran ring closing mechanisms, and will 
require similar mechanisms for removal of the 8-OH function. The 
only previous thiomarinol derivative reported to contain an 8-
hydroxyl is TM-G 6 (as a very minor metabolite of WT 
SANK73390),[1c] but it lacks both the 4 and 6-hydroxyls. We have 
not observed 6 in any of our studies, and its structure remains to 
be confirmed. Further detailed analysis of minor components 
resulted in the isolation of metabolites 23–30. These metabolites 
form two structurally distinct groups. The first consists of 6,7- 
diketothiomarinol C 23, analogous to mupirocin C1 14 isolated 
from ∆mupC, its 4-hydroxy analogue 24, and 25 a 6,7-diketo 
analogue of marinolic acid A6 lacking the 4-hydroxyl and the 
pyrrothine. These all exist as the enol-ketone tautomers shown. 
The second group possesses the 6-hydroxy-7-keto THP ring (7-
keto-thiomarinol C 26 and its 4-hydroxy analogue 27) similar to 
mupirocin F1 15 isolated from ∆mupF, and products (28–30) 
derived from 26 and 27 by keto-enol tautomerism and/or 
epimerisation. This is consistent with a biosynthetic sequence to 
thiomarinol C 2 being similar to mupirocin after the formation of 
the 8-hydroxyTHP ring. Interestingly, the 4-hydroxy analogue of 
8-hydroxy-thiomarinol C was not detected.  
 
Chemical Complementation Experiments 
When PA-A 7 was fed to the PKS mutant strain of SANK73390 in 
which all of the tailoring genes are intact, it was metabolised with 
both 4-hydroxylation and/or pyrrothine addition taking place to 
give the novel mupirocin/thiomarinol hybrid molecules 31-33 
(Scheme 3).[6,13] In this study we have investigated 
biotransformations of further substrates isolated from P. 
fluorescens and the products were isolated and fully 
characterised by spectroscopic methods.   
On feeding PA-C 9, with the mature 6,7-dihydroxypyran ring, the 
pyrrothine was added to give the novel metabolite 36 (MW 638) 
and 4-hydroxylation yielded 37 (MW 654) in similar amounts 
(Scheme 3). In contrast, feeding PA-B 8 or desepoxy-PA-B 17 
simply led to pyrrothine addition (34 and 35, respectively) and no 
C-4 hydroxylated metabolites were detected. Hence it is apparent 
that the presence of an 8-hydroxyl inhibits 4-hydroxylation. 
Desepoxy-mupirocin P 16 was also fed to cultures of the PKS 
mutant giving the 3 metabolites, 35, 36 and 37 all of which had 
the pyrrothine added. Importantly it was evident that further 
processing of the THP ring had occurred leading to loss of the 8-
hydroxyl and keto-reduction giving the fully mature 6,7-
dihydroxylated product 36;  a minor product detected by LC-MS 
was the corresponding 4-hydroxylated metabolite 37. The 6,7,8-
trihydroxy metabolite 35 was formed via a keto-reduction and 
pyrrothine addition, but no loss of the 8-hydroxyl was observed.  
It is interesting to compare the metabolism of 8-hydroxyTHPs in 
P. fluorescens and Pseudoalteromonas. In the former desepoxy 
PA-B 17 (and PA-B 8) undergo efficient oxidation, dehydration 
and keto-reductions to give the bioactive 6,7-diols PA-C 9 (and 
PA-A 7). In contrast, in the PKS mutant of Pseudoalteromonas 
whilst further processing of the 6,8-dihydroxy-7-ketoTHP ring of 
desepoxy-mupirocin P 16 to the mature 6,7-dihydroxyTHP as well 
as pyrrothine addition readily occurs, feeding the  6,7,8-trihydroxy 
THP substrates 8 or 17, only pyrrothine addition was apparent. 
 
 
Scheme 3. Transformation of mupirocin analogues by the PKS mutant strain of 
Pseudoalteromonas SANK73390. 
 Conclusions 
MupP has been identified as a dehydratase involved in mupirocin 
biosynthesis. The mupP strain of P. fluorescens was cultured 
and the novel 6-keto-7-alcohol, mupirocin P 13 was isolated and 
fully characterised. Results of chemical complementation studies 
feeding desepoxy-mupirocin P 16 to the mmpEOR/mupW 
strain blocked earlier in the biosynthetic pathway, are in accord 
with 16 being an intermediate in the biosynthesis of the bioactive 
6,7-diol PA-C 9 (and the epoxy analogue mupirocin P 13 is 
deduced to be a biosynthetic precursor of PA-A 7). Hence the first 
step in conversion of PA-B 8 to PA-A 7 is oxidation at C-6. 
Furthermore feeding 16 to the mupV strain gave PA-C in accord 
with MupV acting before MupP.  
Despite some divergencies in the gene clusters, the isolation of 
novel metabolites including 22, 23 and 26 from cultures of the 
tmlF mutant of SANK73390 point to some similarities in THP ring 
processing in both thiomarinol and mupirocin. Indeed, feeding 
desepoxy-mupirocin P 16 to cultures of the PKS mutant not only 
led to addition of the pyrrothine but also confirmed that further 
processing of the THP ring occurred giving 6,7-dihydroxylated 
products 36 and 37. In contrast, feeding desepoxy-PA-B 17 to the 
PKS mutant strain simply led to addition of the pyrrothine and no 
THP modified products were detected.  PA-B 8 is efficiently 
converted to PA-A 7 by mutant strains of P. fluorescens blocked 
earlier in the biosynthetic pathway indicating an important 
difference between the two pathways.  
Differences are evident in the two gene clusters. Homologues of 
the mupirocin stand-alone ACP MacpE, along with MupU and 
MupV are missing in SANK73390. TmpB, however, contains extra 
KS and ACP domains as compared to MmpB which it is 
speculated may replace the apparently missing activities.[13] Thus 
the tetrahydropyran processing reactions occurring on 
intermediates bound to MacpE, may take place while bound to the 
additional ACP on TmpB, thus obviating the need for homologues 
of MacpE and MupU. The lack of ring processing of PA-B 8 and 
desepoxy-PA-B 17 fed to the PKS mutant of Pseudoalteromonas 
thus may be rationalised by an inability of these substrates to be 
loaded onto TmpB so providing key evidence to support our 
proposed pathway to the marinolic acids. Structure-activity 
studies as well as investigations to fully understand the 
differences between the two pathways and to identify the genes 
for 4- and 6-hydroxylation in thiomarinol and 6-hydroxylation in 
mupirocin biosynthesis are in progress. 
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